These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36941816)

  • 41. Spotlight on the Mucormycosis Outbreak: A Deadly Fungal Infection That Followed the COVID-19 Pandemic.
    Patel SN; Shah S; Panchal J; Desai C; Upadhya IB; Patel M
    Cureus; 2023 Feb; 15(2):e35095. PubMed ID: 36938207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management.
    Rudrabhatla PK; Reghukumar A; Thomas SV
    Acta Neurol Belg; 2022 Apr; 122(2):273-280. PubMed ID: 34820787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The "Black Fungus" in India: The Emerging Syndemic of COVID-19-Associated Mucormycosis.
    Gandra S; Ram S; Levitz SM
    Ann Intern Med; 2021 Sep; 174(9):1301-1302. PubMed ID: 34097436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Late diagnosis of rhinocerebral mucormycosis in patients with COVID-19 (case studies)].
    Kurysheva NI; Kapkova SG; Naumova VI; Smolev DM; Lishchuk SV; Nekrasova EY; Kim VE
    Vestn Oftalmol; 2023; 139(6):110-121. PubMed ID: 38235637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19-associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico.
    Guzmán-Castro S; Chora-Hernandez LD; Trujillo-Alonso G; Calvo-Villalobos I; Sanchez-Rangel A; Ferrer-Alpuin E; Ruiz-Jimenez M; Corzo-Leon DE
    Mycoses; 2022 Jan; 65(1):65-70. PubMed ID: 34674319
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Case Report: Rhino-orbital Mucormycosis Related to COVID-19: A Case Series Exploring Risk Factors.
    Aggarwal SK; Kaur U; Talda D; Pandey A; Jaiswal S; Kanakan A; Singh A; Chakrabarti SS
    Am J Trop Med Hyg; 2021 Dec; 106(2):566-570. PubMed ID: 34902834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coincidence or reality behind Mucormycosis, diabetes mellitus and Covid-19 association: A systematic review.
    Sengupta I; Nayak T
    J Mycol Med; 2022 Aug; 32(3):101257. PubMed ID: 35219907
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rhino-orbital-cerebral mucormycosis: An epidemiological study from a tertiary care referral center in Western India.
    Patel R; Jethva J; Bhagat PR; Prajapati V; Thakkar H; Prajapati K
    Indian J Ophthalmol; 2022 Apr; 70(4):1371-1375. PubMed ID: 35326057
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is Mucormycosis an inevitable complication of Covid-19 in India?
    Bhogireddy R; Krishnamurthy V; Jabaris S SL; Pullaiah CP; Manohar S
    Braz J Infect Dis; 2021; 25(3):101597. PubMed ID: 34289382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vitamin A Deficiency, COVID-19, and Rhino-Orbital Mucormycosis (Black Fungus): An Analytical Perspective.
    Sarohan AR; Edipsoy S; Özkurt ZG; Özlü C; Demir AN; Cen O
    Adv Exp Med Biol; 2023; 1436():153-166. PubMed ID: 37253944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
    Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
    Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study.
    Avatef Fazeli M; Rezaei L; Javadirad E; Iranfar K; Khosravi A; Amini Saman J; Poursabbagh P; Ghadami MR; Parandin MM; Dehghani A; Ahmadi Jouybari T; Mahdavian B; Eivazi N; Rezaei S; Rezaei A; Emami B; Haqgou M; Bozorgomid A; Sayad B
    Mycoses; 2021 Nov; 64(11):1366-1377. PubMed ID: 34252988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mucormycosis infection associated with global COVID-19 pandemic - an institutional histopathological study.
    Keerthika R; Narwal A; Kamboj M; Devi A; Anand R; N S; Singh V; Agarwal V; Gupta A
    Med Oral Patol Oral Cir Bucal; 2023 Mar; 28(2):e99-e107. PubMed ID: 36806020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The baneful alliance of COVID-19 and mucormycosis: Histopathological concerns.
    Singh A; Kumar V; Kumar V; Verma N
    Indian J Pathol Microbiol; 2023; 66(1):106-110. PubMed ID: 36656220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A systematic review on SARS-CoV-2-associated fungal coinfections.
    Soni S; Namdeo Pudake R; Jain U; Chauhan N
    J Med Virol; 2022 Jan; 94(1):99-109. PubMed ID: 34570905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post-Covid alliance-mucormycosis, a fatal sequel to the pandemic in India.
    Nambiar M; Varma SR; Damdoum M
    Saudi J Biol Sci; 2021 Nov; 28(11):6461-6464. PubMed ID: 34305427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucormycosis: The hidden and forgotten disease.
    Darwish RM; AlMasri M; Al-Masri MM
    J Appl Microbiol; 2022 Jun; 132(6):4042-4057. PubMed ID: 35156271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of COVID with Mycosis in General.
    Kaur G; Kaur R; Sumanpreet ; Kaur M
    Infect Disord Drug Targets; 2024; 24(6):e190124225866. PubMed ID: 38251692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.
    Sharma R; Kumar P; Rauf A; Chaudhary A; Prajapati PK; Emran TB; Gonçalves Lima CM; Conte-Junior CA
    Front Cell Infect Microbiol; 2022; 12():937481. PubMed ID: 35923801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes.
    Osaigbovo II; Ekeng BE; Davies AA; Oladele RO
    Mycoses; 2023 Jul; 66(7):555-562. PubMed ID: 36856432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.